Thailand considering limits on AstraZeneca vaccine exports



* Curbs would hurt vaccine efforts for neighbours

* Thailand battling worst outbreak, low vaccine rate

* Plan agreed in principle - Thai official (Updates with AstraZeneca statement)

By Panarat Thepgumpanat and Panu Wongcha-um

BANGKOK, July 14 (Reuters) - Thailand is considering imposing limits on exports of locally manufactured AstraZeneca AZN.L COVID-19 vaccines to fight its own crisis, an official said on Wednesday, a move likely to impact neighbours and stir concerns of vaccine protectionism.

Any attempt to regulate exports could further slow vaccine rollout to Malaysia, Vietnam and Indonesia, which are also battling spikes in infections and supply disruptions caused by earlier export curbs imposed by India.

The move also marks a fresh setback to AstraZeneca, which had initial delays in regional production and delivery and hoped to put it back on track from this month and meet its supply commitments to the region.

Nakorn Premsri, a key member of the National Vaccine Committee, told reporters when asked about a plan to place a quota on vaccine exports that the committee had "agreed in principle" on such a draft order.

"Right now, the order has not been issued yet," Nakorn said, adding that various agencies will need to review it and consider its impacts.

He did not address at what levels export quotas might be set.

Thailand is suffering its worst coronavirus outbreak yet, with hundreds of deaths in recent weeks and more than 8,000 new infections reported on many days this month - and only about 5% of its more than 66 million population is fully vaccinated.

AstraZeneca said in a statement its Thailand-manufactured vaccine "is of critical importance" to neighbouring countries where the pandemic is also accelerating.

"We are actively working with the government in Thailand and governments across Southeast Asia to continue to deliver equitable vaccine access to the region," the statement said.

In late June, AstraZeneca Thailand said its partner Siam Bioscience, owned by King Maha Vajiralongkorn, would produce 180 million doses this year, just over a third for Thailand and two thirds for elsewhere in Southeast Asia.

"Right now we will talk with the vaccine manufacturer so they can deliver the vaccine to Thailand in a suitable manner that matches the outbreak situation in the country," Nakorn told reporters.

AstraZeneca delivered 6 million doses, as promised, to Thailand in June when the country's mass vaccine rollout started. A Thai official last month said a similar volume would be delivered in July, short of the previously announced 10 million monthly doses.

Thailand has been producing the AstraZeneca vaccine since June and is slated to export it to several other countries in Southeast Asia, as well as Taiwan. The Philippines and Malaysia are among countries that have experienced delivery delays.

Thailand's government has so far used the AstraZeneca's viral vector vaccine and Sinovac SVA.O inactivated virus vaccine.
Additional reporting by Kay Johnson; Writing by Panu Wongcha-um; Editing by Martin Petty, Ed Davies and Alison Williams

Disclaimer: Ang mga kabilang sa XM Group ay nagbibigay lang ng serbisyo sa pagpapatupad at pag-access sa aming Online Trading Facility, kung saan pinapahintulutan nito ang pagtingin at/o paggamit sa nilalaman na makikita sa website o sa pamamagitan nito, at walang layuning palitan o palawigin ito, at hindi din ito papalitan o papalawigin. Ang naturang pag-access at paggamit ay palaging alinsunod sa: (i) Mga Tuntunin at Kundisyon; (ii) Mga Babala sa Risk; at (iii) Kabuuang Disclaimer. Kaya naman ang naturang nilalaman ay ituturing na pangkalahatang impormasyon lamang. Mangyaring isaalang-alang na ang mga nilalaman ng aming Online Trading Facility ay hindi paglikom, o alok, para magsagawa ng anumang transaksyon sa mga pinansyal na market. Ang pag-trade sa alinmang pinansyal na market ay nagtataglay ng mataas na lebel ng risk sa iyong kapital.

Lahat ng materyales na nakalathala sa aming Online Trading Facility ay nakalaan para sa layuning edukasyonal/pang-impormasyon lamang at hindi naglalaman – at hindi dapat ituring bilang naglalaman – ng payo at rekomendasyon na pangpinansyal, tungkol sa buwis sa pag-i-invest, o pang-trade, o tala ng aming presyo sa pag-trade, o alok para sa, o paglikom ng, transaksyon sa alinmang pinansyal na instrument o hindi ginustong pinansyal na promosyon.

Sa anumang nilalaman na galing sa ikatlong partido, pati na ang mga nilalaman na inihanda ng XM, ang mga naturang opinyon, balita, pananaliksik, pag-analisa, presyo, ibang impormasyon o link sa ibang mga site na makikita sa website na ito ay ibibigay tulad ng nandoon, bilang pangkalahatang komentaryo sa market at hindi ito nagtataglay ng payo sa pag-i-invest. Kung ang alinmang nilalaman nito ay itinuring bilang pananaliksik sa pag-i-invest, kailangan mong isaalang-alang at tanggapin na hindi ito inilaan at inihanda alinsunod sa mga legal na pangangailangan na idinisenyo para maisulong ang pagsasarili ng pananaliksik sa pag-i-invest, at dahil dito ituturing ito na komunikasyon sa marketing sa ilalim ng mga kaugnay na batas at regulasyon. Mangyaring siguruhin na nabasa at naintindihan mo ang aming Notipikasyon sa Hindi Independyenteng Pananaliksik sa Pag-i-invest at Babala sa Risk na may kinalaman sa impormasyong nakalagay sa itaas, na maa-access dito.

Gumagamit kami ng cookies para mabigyan ka ng mahusay na karanasan sa aming website. Magbasa pa o palitan ang iyong cookie settings.

Babala sa Risk: Ang iyong kapital ay maaaring malugi. Ang mga produktong naka-leverage ay maaaring hindi para sa lahat. Tingnan ang aming Risk Disclosure.